{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.7","upperLimit":"63.9","value":"50.8"},{"groupId":"OG001","lowerLimit":"42.5","upperLimit":"68.1","value":"55.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"Disease Control Rate was defined as the percentage of participants who achieved confirmed CR or PR or had demonstrated stable disease (SD) for at least 24 weeks prior to any evidence of progression. Complete Response: disappearance of all target lesions. Partial Response: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Stable Disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum diameters while on study. Progressive Disease: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm. or the appearance of new lesion(s). Participants in the analysis population with missing DCR were considered as disease not under control. The data cutoff date was 19-Feb-2021.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan. Cohort A participants received pembrolizumab 200 mg intravenously (IV) on Day 1 of every 3-week cycle (Q3W) for up to approximately 35 cycles (up to approximately 2 years).","id":"OG000","title":"Cohort A - Pembrolizumab 200 mg"},{"description":"Participants were previously treated with at least one line of systemic standard of care therapy: fluoropyrimidine + oxaliplatin or fluoropyrimidine + irinotecan +/ - anti vascular endothelial growth factor (VEGF)/ epidermal growth factor regulator (EGFR) monoclonal antibody. Cohort B participants received pembrolizumab 200 mg IV on Day 1 Q3W for up to approximately 35 cycles (up to approximately 2 years).","id":"OG001","title":"Cohort B - Pembrolizumab 200 mg"}],"paramType":"NUMBER","populationDescription":"The analysis population consisted of all participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 66 months","title":"Disease Control Rate (DCR) Per RECIST 1.1 Assessed by Central Imaging Vendor.","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}